Are the screening guidelines for branch duct intraductal papillary mucinous neoplasms cost-effective in an Australian setting?

This cost analysis demonstrates that screening of 2-3 cm BD-IPMN according to current guidelines is unlikely to be cost-effective in an Australian context. To determine the true ICER, a cost analysis on real-world data is required.